Loading stock data…
$1.47-0.01 (-1.01%)
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
ProQR Therapeutics N.V. in the Healthcare sector is trading at $1.47 with a market capitalization of $262M. Wall Street consensus targets $7.78 (9 analysts), implying a +430.9% move over the next 12 months. The stock is currently near its 52-week low of $1.33, remaining 15.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.76M↑ | $2.03M↓ | $4.69M↑ | $2.88M↓ | $3.82M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$8.82M↑ | -$13.65M↓ | -$9.10M↑ | -$11.28M↑ | -$12.25M |
| Net Income | -$8.73M↑ | -$13.38M↓ | -$8.92M↑ | -$11.01M↑ | -$12.18M |
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders wi...